HER2 Mutations Present Unique Challenges in NSCLC

In Brief for Nov. 9, 2022

Targeted Therapies Expanding for MET Dysregulation in NSCLC

Undruggable No More: KRAS Experts Review What is Known—and Unknown—About This Challenging Alteration

Guideline-Concordant Surgery, Adjuvant Therapy, and the Promise of Curative-Intent Lung Cancer Surgery: What Are We Up Against?

From the Editor: Looking Back on 2022

In Brief for Dec. 21, 2022

IASLC Announces New JTO CRR Editor-in-Chief

ILCN Names New Associate Editors

In Brief for January 25, 2023

Increasing Evidence Demonstrates the Usefulness of ctDNA

Committee Update: Advocates Offer Unique Support to Members, Help Investigators Understand Patients